Bisphosphonate-related Osteonecrosis of the Jaw: a Review of the Literature

Overview

Journal Int J Dent

Publisher Wiley

Specialty Dentistry

Date 2014 May 29

PMID 24868206

Citations 14

Authors

Eder Alberto Sigua-Rodriguez

Renato da Costa Ribeiro

Ana Caroline Ramos de Brito

Natalia Alvarez-Pinzon

Jose Ricardo de Albergaria-Barbosa

Affiliations

Soon will be listed here.

Abstract

Bisphosphonates (BPs) are a class of drugs used to treat osteoporosis and malignant bone metastasis. BPs show high binding capacity to the bone matrix, especially in sites of active bone metabolism. The American Society for Bone and Mineral Research defines BRONJ as "an area of exposed bone in the maxillofacial region that has not healed within 8 weeks after identification by a healthcare provider in a patient who is receiving or has been exposed to a bisphosphonate and has not had radiation therapy to the craniofacial region." Bisphosphonate-related osteonecrosis of the jaw (BRONJ) can adversely affect quality of life, as it may produce significant morbidity. The American Association of Oral and Maxillofacial Surgeons (AAOMS) considers as vitally important that information on BRONJ be disseminated to other dental and medical specialties. The purpose of this work is to offer a perspective on how dentists should manage patients on BPs, to show the benefits of accurately diagnosing BRONJ, and to present diagnostic aids and treatments strategies for the condition.

Citing Articles

Osteonecrosis of the Jaws: An Update and Review of Literature.

Kalita F, Gupta D, Gehlot N, Mitra S, Singh S, Pillai S J Maxillofac Oral Surg. 2023; 22(2):344-351.

PMID: 37122785 PMC: 10130280. DOI: 10.1007/s12663-023-01876-w.

Interventions for managing medication-related osteonecrosis of the jaw.

Beth-Tasdogan N, Mayer B, Hussein H, Zolk O, Peter J Cochrane Database Syst Rev. 2022; 7:CD012432.

PMID: 35866376 PMC: 9309005. DOI: 10.1002/14651858.CD012432.pub3.

Schemes for Drug-Induced Treatment of Osteonecrosis of Jaws with Particular Emphasis on the Influence of Vitamin D on Therapeutic Effects.

Michalak F, Hnitecka S, Dominiak M, Grzech-Lesniak K Pharmaceutics. 2021; 13(3).

PMID: 33800247 PMC: 7999491. DOI: 10.3390/pharmaceutics13030354.

The roles of osteocytes in alveolar bone destruction in periodontitis.

Huang X, Xie M, Xie Y, Mei F, Lu X, Li X J Transl Med. 2020; 18(1):479.

PMID: 33308247 PMC: 7733264. DOI: 10.1186/s12967-020-02664-7.

Imaging and histomorphometric evaluation of mandible and tibia of rats treated with bisphosphonates.

Martelli S, Damian M, Schinestsck A, Schuch L, Cascaes A, Vasconcelos A Oral Maxillofac Surg. 2019; 23(4):473-479.

PMID: 31686251 DOI: 10.1007/s10006-019-00807-9.

References

Crepin S, Laroche M, Sarry B, Merle L . Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review. Eur J Clin Pharmacol. 2010; 66(6):547-54. DOI: 10.1007/s00228-010-0822-5. View

Mortensen M, Lawson W, Montazem A . Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review. Laryngoscope. 2007; 117(1):30-4. DOI: 10.1097/01.mlg.0000240885.64568.9e. View

Borgioli A, Viviani C, Duvina M, Brancato L, Spinelli G, Brandi M . Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations. Ther Clin Risk Manag. 2009; 5(1):217-27. PMC: 2697532. DOI: 10.2147/tcrm.s1697. View

Nase J, Suzuki J . Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc. 2006; 137(8):1115-9. DOI: 10.14219/jada.archive.2006.0350. View

Montebugnoli L, Felicetti L, Gissi D, Pizzigallo A, Pelliccioni G, Marchetti C . Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 104(4):473-7. DOI: 10.1016/j.tripleo.2007.01.008. View

Lin J, DUGGAN D, CHEN I, Ellsworth R . Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos. 1991; 19(5):926-32. View

Edwards B, Gounder M, McKoy J, Boyd I, Farrugia M, Migliorati C . Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008; 9(12):1166-72. DOI: 10.1016/S1470-2045(08)70305-X. View

Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova M, Di Lenarda R . Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol. 2006; 35(4):236-43. DOI: 10.1259/dmfr/27458726. View

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

10.

Diel I, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J . Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?. Crit Rev Oncol Hematol. 2007; 64(3):198-207. DOI: 10.1016/j.critrevonc.2007.07.005. View

11.

Marx R, Cillo Jr J, Ulloa J . Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65(12):2397-410. DOI: 10.1016/j.joms.2007.08.003. View

12.

Fleisch H, Russell R, Francis M . Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969; 165(3899):1262-4. DOI: 10.1126/science.165.3899.1262. View

13.

Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis C . Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009; 27(32):5356-62. DOI: 10.1200/JCO.2009.21.9584. View

14.

Walter C, Grotz K, Kunkel M, Al-Nawas B . Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer. 2006; 15(2):197-202. DOI: 10.1007/s00520-006-0120-z. View

15.

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

16.

Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye J . Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer. 2006; 6:60. PMC: 1434759. DOI: 10.1186/1471-2407-6-60. View

17.

Barni S, Mandala M, Cazzaniga M, Cabiddu M, Cremonesi M . Bisphosphonates and metastatic bone disease. Ann Oncol. 2006; 17 Suppl 2:ii91-95. DOI: 10.1093/annonc/mdj935. View

18.

Marx R, Sawatari Y, Fortin M, Broumand V . Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63(11):1567-75. DOI: 10.1016/j.joms.2005.07.010. View

19.

Berte R, Arcari A, Bernuzzi P, Anselmi E, Lazzaro A, Moroni C . Jaw avascular bone necrosis associated with long-term use of bisphosphonates. Tumori. 2006; 92(4):361. DOI: 10.1177/030089160609200419. View

20.

Kumar V, Pass B, Guttenberg S, Ludlow J, Emery R, Tyndall D . Bisphosphonate-related osteonecrosis of the jaws: a report of three cases demonstrating variability in outcomes and morbidity. J Am Dent Assoc. 2007; 138(5):602-9. DOI: 10.14219/jada.archive.2007.0230. View